Skip to content

Registry for Hypoparathyroidism Wuerzburg

Registry and Biobank for Patients With Hypoparathyroidism Wuerzburg

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05585593
Enrollment
300
Registered
2022-10-19
Start date
2017-10-18
Completion date
2032-01-01
Last updated
2022-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comorbidities and Coexisting Conditions, Hypercalcemia, Hypocalcemia, Morality, Quality of Life

Brief summary

Long-term conventional treatment of chronic hypoparathyroidism does not fully restore calcium homeostasis leading to increased morbidity, emergency events and reduced subjective health status. To further investigate general morbidity, hypocalcemic events, subjective and daily life performance in patients with chronic hypoparathyroidism a standardized interview as well as blood sampling and examinations such as echocardiography and renal ultrasound are performed.

Detailed description

Design: In a longitudinal prospective trial the comorbidities, mortality, hypocalcemic and hypercalcemic events and quality of life in patients with chronic hypoparathyroidism will be evaluated by a standardized interview, blood sampling and further examinations such as echocardiography and renal ultrasound. Patients: Patients will be recruited out of the patient population of the University Hospital Wuerzburg. Statistical Analysis: Documentation and analysis will be performed at the Department of Medicine I, Endocrine and Diabetes Unit, University of Würzburg, Germany. Data will be documented after pseudonymisation in a data base. For further analysis data will be compared to sex- and age-matched controls.

Interventions

None listed

Sponsors

University of Wuerzburg
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age of 18 * chronic hypoparathyroidism (\>12 months) under established therapy or chronic pseudohypoparathyroidism (\>12 months) under established therapy * written informed consent

Exclusion criteria

* age \<18 years * no detailed documentation of hypo- or pseudohypoparathyroidism

Design outcomes

Primary

MeasureTime frameDescription
Comorbidites15 yearsComorbidities such as renal diseases, cardiovascular disease, psychiatric diseases under treatment
Subjective health status15 yearsAssessment of the subjective health status by standardized quality of life (QoL) questionnaires (e.g. short form-36, Patient Health Questionnaire 28)

Secondary

MeasureTime frameDescription
Hypocalcemic and hypercalcemic events15 yearsdocumentation of frequency of hypocalcemia under standard treatment
Mortality15 years

Countries

Germany

Contacts

Primary ContactStefanie Hahner, MD
hahner_s@ukw.de0931/201-39200

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026